The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Evaluation of miR 31 3p as a biomarker of prognosis and panitumumab benefit in RAS-wt advanced colorectal cancer (aCRC): Analysis of patients (pts) from the PICCOLO trial.
 
Pierre Laurent-Puig
Honoraria - Amgen; Boehringer Ingelheim; IntegraGen; Merck Serono; Sanofi
Consulting or Advisory Role - Amgen; Boehringer Ingelheim; IntegraGen; Merck Serono; Sanofi
Patents, Royalties, Other Intellectual Property - Université paris Descartes
 
Sophie Paget-Bailly
No Relationships to Disclose
 
Dewi Vernerey
No Relationships to Disclose
 
Celine Vazart
Employment - IntegraGen
 
Virginie Decaulne
Employment - IntegraGen
 
Karine Fontaine
Employment - IntegraGen
 
Francis Rousseau
Employment - IntegraGen
 
Faye Elliott
No Relationships to Disclose
 
Philip Quirke
Research Funding - Genentech (Inst); Illumina (Inst); IntegraGen (Inst)
 
Susan Richman
No Relationships to Disclose
 
Jenny Seligman
No Relationships to Disclose
 
Matthew T. Seymour
Research Funding - IntegraGen (Inst)
 
Franck Bonnetain
Consulting or Advisory Role - IntegraGen; Merck Serono; Roche Pharma AG
Research Funding - Roche Pharma AG
Travel, Accommodations, Expenses - Merck Serono; Roche Pharma AG
 
Francois Liebaert
Employment - IntegraGen
 
Raphaële Thiébaut
Employment - IntegraGen
Patents, Royalties, Other Intellectual Property - IntegraGen (Inst)